The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...

Regeneron Pharmaceuticals (NASDAQ:REGN) said on Thursday that the U.S. FDA will be reviewing the supplemental biologics license application ((sBLA)) for Eylea HD injection, 8 mg, to treat macular ...

Findings that U.S. companies can sue foreign rivals despite limited business operations in the country could dissuade drug ...

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid  Approval based on pivotal results showing improvements in sustained disease remission and ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use co ...

TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent ® (dupilumab) ...

The agreement, involving an upfront payment of $80 million and potential milestone payments up to $1.93 billion, aims to enhance Regeneron's obesity and metabolic programs by potentially offering ...